FBI Probes Jim Irsay Death Over Prescription Drugs, Ketamine Use and Doctor Relationship: Report
FBI Investigation into Jim Irsay’s Death and Prescription Drug Use
Federal authorities have opened an investigation into the death of Jim Irsay, the longtime owner of the Indianapolis Colts, with a particular focus on his use of prescription medications, ketamine treatments, and his connection to a California-based addiction doctor. According to reports, the FBI issued a federal grand jury subpoena earlier this month to obtain records related to Irsay’s death, his alleged use of both illegal and prescription drugs, and his medical treatment under Dr. Harry Haroutunian, an addiction specialist who treated Irsay in the months leading up to his passing.
The investigation also included several days of activity in Indianapolis, where agents gathered information as part of the inquiry. While the FBI has declined to comment publicly on the probe, Colts officials have acknowledged awareness of subpoenas but denied that the team or its employees have been directly contacted. Dan Emerson, the Colts’ Chief Legal Officer, confirmed to The Washington Post that no subpoenas had been served to the organization or its staff.
Details Surrounding Jim Irsay’s Health and Medical Treatment
Jim Irsay, who owned the Colts since 1997 and was deeply involved in the team’s operations, died in May at the age of 65. His death certificate, signed by Dr. Haroutunian, lists cardiac arrest caused by acute pneumonia as the primary cause, with underlying heart conditions noted as contributing factors. Notably, no official autopsy was performed following his death.
Throughout his life, Irsay faced numerous health challenges, including a well-documented battle with drug and alcohol addiction. He openly admitted to attending rehabilitation at least 15 times. In January 2024, the Colts announced that Irsay was being treated for a severe respiratory illness, and by February, he had shared on social media that he was “on the mend.”
In December 2023, law enforcement responded to a call at Irsay’s home in the early morning hours, finding him unresponsive and cold in bed during what was described as a “suspected overdose.” Irsay later disputed the overdose claim, stating that the media’s quick assumptions were unfair given his history.
Reports indicate that Dr. Haroutunian prescribed Irsay more than 200 opioid pills in the months before the December incident. Additionally, ketamine treatments were administered during a period when Irsay was reportedly experiencing a relapse. The overdose events reportedly occurred both at his Indianapolis residence and a rental property in Miami.
Background on Jim Irsay and His Legacy with the Colts
Jim Irsay’s connection to the Colts spanned decades. His father purchased the team in 1972 when it was based in Baltimore and relocated it to Indianapolis in 1984. Irsay served as the team’s general manager from 1982 until 1996, and upon his father’s death in 1997, he became the youngest NFL owner at age 37.
Under his leadership, the Colts achieved significant success, winning 258 games—ranking fourth in the NFL during that period—securing 10 division titles, making 18 playoff appearances, and competing in two Super Bowls with a 1-1 record.
Despite his professional achievements, Irsay’s personal struggles with substance abuse were public knowledge. In 2014, he was arrested and pleaded guilty to operating while intoxicated, which resulted in a six-game suspension and a $500,000 fine from the NFL. Irsay attributed some of the scrutiny he faced to his status as a White billionaire.
Implications of the FBI Probe on Prescription Drug Use and Medical Oversight
The FBI’s investigation into Jim Irsay’s death highlights growing concerns about prescription drug practices, especially involving high-profile individuals with histories of addiction. The focus on Dr. Harry Haroutunian’s role raises questions about medical oversight and the prescribing of opioids and ketamine in addiction treatment.
Ketamine, while used in some cases to treat depression and addiction, carries risks and is subject to strict medical guidelines. The fact that Irsay received ketamine treatments amid a relapse period underscores the complexity of managing chronic addiction and the potential dangers when treatment protocols are not carefully monitored.
The investigation may also shed light on the broader issue of prescription drug abuse and the responsibilities of healthcare providers in preventing misuse. As the probe continues, it could lead to changes in how addiction specialists prescribe medications and manage patients with complicated health and addiction histories.
Reactions from the Colts Organization and the Public
The Indianapolis Colts have issued a statement acknowledging awareness of the FBI investigation but emphasized that they have not been contacted by federal authorities or served with any subpoenas. The organization has remained largely silent on the specifics of the probe, focusing instead on honoring Irsay’s legacy.
Fans and the public have expressed mixed reactions, with many sympathizing with Irsay’s struggles and others calling for transparency regarding the circumstances of his death. The case has sparked conversations about addiction, mental health, and the pressures faced by high-profile sports executives.
Conclusion
The FBI’s ongoing investigation into Jim Irsay’s death, prescription drug use, ketamine treatments, and his relationship with Dr. Harry Haroutunian shines a light on the complex intersection of addiction, medical treatment, and accountability. As more details emerge, this case may influence how addiction treatment is approached and how prescription drugs are managed for vulnerable individuals.
If you or someone you know is struggling with addiction or prescription drug use, it’s important to seek professional help. Stay informed and support efforts to improve addiction treatment and medical oversight by following trusted news sources and health organizations.
